Results 141 to 150 of about 2,320,248 (308)

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Delivery of HIV partner services in the United States and dependent areas 2021 [PDF]

open access: yes
In 2020, there were 30,692 persons with newly diagnosed HIV infection in the United States.1 Most infections occur following exposure to HIV from persons who are infected but not receiving medical care.2 Some of these persons have HIV that has not been ...

core  

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian   +5 more
wiley   +1 more source

Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model‐Based Analysis of Mother–Infant Pairs for Tuberculosis Prevention

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
IMPAACT 2001 (NCT02651259) evaluated the safety and pharmacokinetics (PK) of once‐weekly isoniazid and rifapentine in pregnant and postpartum women for tuberculosis prevention. Rifapentine (RPT) and desacetyl rifapentine (desRPT) PK data were collected in maternal plasma, breast milk, infant cord blood, and infant plasma.
Priya Jayachandran   +18 more
wiley   +1 more source

HIV/AIDS and STD Semiannual Report Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report HIV/AIDS in Kansas Biannual Report ... HIV/AIDS in Kansas Annual Report ...

open access: yes, 2009
Contains Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report "HIV/AIDS and STD Semiannual Report is a publication of the Kansas Department of Health and Environment with funding assistance from the Centers for Disease ...
HIV/AIDS Surveillance Program
core  

Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre‐exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Shawnalyn W. Sunagawa   +11 more
wiley   +1 more source

Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antiretroviral pre‐exposure prophylaxis (PrEP) is less effective in women than expected, partly because drug exposure within the female genital tract is variable and may be influenced by the vaginal microbiome. We developed an integrated pharmacometrics and machine learning framework to evaluate associations between vaginal microbiome composition and ...
Diqin Yan   +6 more
wiley   +1 more source

HIV/AIDS and STD Semiannual Report Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report HIV/AIDS in Kansas Biannual Report ... HIV/AIDS in Kansas Annual Report ...

open access: yes, 2008
Contains Incident, Prevalent, and Cumulative AIDS Cases in Kansas as of ... by Date of Report "HIV/AIDS and STD Semiannual Report is a publication of the Kansas Department of Health and Environment with funding assistance from the Centers for Disease ...
[HIV/AIDS Surveillance Program]
core  

Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL‐C Lowering

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Enlicitide decanoate is a macrocyclic peptide first‐in‐class oral PCSK9 inhibitor that lowers LDL‐C, with maximal efficacy achieved when administered on an empty stomach. This work characterizes the effects of food, pre‐dose fasting duration (2–8 hours), water volume, common beverages (black coffee and plain tea), and other real‐world scenarios on ...
Douglas G. Johns   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy